Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States

BACKGROUND: Omalizumab was approved for the treatment of chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) in the United States in March 2014. OBJECTIVE: This study sought to describe real-world omalizumab use, in the United States, in a large cohort of patients with CIU/CSU. ME...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Allergy Asthma Proc
Main Authors: Eghrari-Sabet, Jacqueline, Sher, Ellen, Kavati, Abhishek, Pilon, Dominic, Zhdanava, Maryia, Balp, Maria-Magdalena, Lefebvre, Patrick, Ortiz, Benjamin, Bernstein, Jonathan A.
Formato: Artigo
Idioma:Inglês
Publicado em: OceanSide Publications, Inc. 2018
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5911510/
https://ncbi.nlm.nih.gov/pubmed/29458456
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2500/aap.2018.39.4132
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados